|Home | About | Journals | Submit | Contact Us | Français|
A 52-year-old man presented with upper abdominal pain and weight loss of 10 kg over 6 months. He had suffered from diabetes mellitus for the past 10 years and was on oral antidiabetic agents. He did not drink alcoholic. He had a history suggestive of steatorrhoea, which worsened following the intake of a fat-rich meal. On clinical examination, his body mass index was 20.5 kg/m2 and there was no evidence of nutritional deficiencies. Abdominal examination was unremarkable. His biochemical evaluation was as follows—haemoglobin 12.7 g/dL (normal range (N) 13–18), glycated haemoglobin 10.5% (N <5.7), S.alkaline phosphatase 90 U/L (N 40–125), serum creatine: 0.9 mg/dL (N 0.6–1.2). An abdomen X-ray showed pancreatic calcification (figure 1). CT scan of the abdomen displayed the presence of a focal hypodense lesion, 4.4×3.7×3.3 cm, in the head of the pancreas, with multiple instances of chunky ductal calcification (figure 2A). MRI of the abdomen showed a T2-hyperintense diffusion restricted, exophytic focal lesion in the head of the pancreas (figure 2B). The patient's blood level for tumour marker Ca 19.9 was 924 (N 0–33). A diagnosis of fibrocalcific pancreatic diabetes (FCPD) with carcinoma of the head of the pancreas was performed. An endoscopic ultrasound guided biopsy from the mass confirmed the diagnosis. A multidisciplinary team discussion was held and treatment modalities including surgery were explained. The patient declined consent for Whipple procedure (pancreaticoduodenectomy) and hence was initiated on palliative chemotherapy with albumin bound paclitaxel (Abraxane) and gemcitabine.
Tropical calcific pancreatitis (TCP) is a distinct variety of chronic pancreatitis, with a high prevalence being reported from southern India. The clinical presentation of TCP includes abdominal pain, steatorrhoea and weight loss, usually in early adulthood. The imaging classically shows multiple chunky calcifications in the pancreatic duct. Patients usually develop exocrine and endocrine dysfunction. When TCP progresses to diabetes, the condition is known as FCPD. Management of FCPD comprises of pancreatic enzyme supplementation and insulin therapy for diabetes.1 These patients are at a higher risk of developing pancreatic cancer (about 100-fold) as compared to those with other forms of pancreatitis.2 Anorexia with or without abdominal pain and progressive weight loss are typical features, so these patients need to be evaluated for occult pancreatic malignancy. The tumour marker CA19-9 is elevated in 70–80% of patients with pancreatic cancer and serial measurements during follow-up are useful to monitor for the development of malignancy.3
The authors thank Banu Shankar for secretarial help.
Contributors: KEC and SS wrote the manuscript. NK and TVP reviewed and revised the manuscript. KEC, SS, NK and TVP approved the final manuscript.
Competing interests: None.
Patient consent: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.